Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced melanoma and normal serum lactate dehydrogenase (LDH).
Melanoma
DRUG: Tesetaxel
Response rate (RECIST), 12 months from date of first dose of study medication
Proportion of patients with a confirmed complete or partial response at least 3 months in duration, 12 months from date of first dose of study medication|Disease control rate (ie, the proportion of patients with a confirmed complete or partial response of any duration or stable disease at least 3 months in duration), 12 months from date of first dose of study medication|Durable response rate (ie, the proportion of patients with a confirmed complete or partial response at least 6 months in duration), 12 months from date of first dose of study medication|Duration of response, 12 months from date of first dose of study medication|Adverse events, Through 30 days post last dose of study medication
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced melanoma and normal serum lactate dehydrogenase (LDH).